降尿酸治疗期间痛风石成分的变化:双能CT研究
本研究对32例痛风患者在接受别嘌醇降尿酸治疗2年期间进行系列双能CT扫描,共分析103个痛风石。结果显示血清尿酸从基线0.43 mmol/L降至第2年0.31 mmol/L,痛风石总体积从5.17 cm³降至2.61 cm³,尿酸体积减少70.6%,软组织体积减少37.8%,尿酸与软组织比值从0.15降至0.05。结论认为痛风石成分在降尿酸治疗期间是动态变化的,软组织成分消退较慢。
要点
- 降尿酸治疗2年后,痛风石尿酸体积减少70.6%,软组织体积仅减少37.8%。
- 痛风石尿酸与软组织比值从基线0.15降至第2年0.05。
- 痛风石软组织成分消退较慢,可能在无可测尿酸结晶沉积后仍持续存在。
核心结论
- 痛风石的成分是动态的,在痛风管理的降尿酸治疗期间会发生变化。
- 痛风石的软组织成分消退较慢,可能在无可测尿酸单钠结晶沉积后仍持续存在。
研究设计与样本
- 本研究为双能CT研究,对32例痛风患者在别嘌醇治疗2年期间进行系列双能CT扫描,别嘌醇剂量递增至血清尿酸<0.36 mmol/L。
- 每例患者最多选取5个指标痛风石,共103个独立痛风石纳入分析。
- 采用常规CT和双能CT扫描的手动勾画方法,对同一指标痛风石系列测量总痛风石体积和尿酸体积,并通过总痛风石体积减去尿酸体积计算软组织体积。
主要发现
- 平均±标准差血清尿酸从基线0.43±0.03 mmol/L降至第2年0.31±0.02 mmol/L。
- 平均±标准差总痛风石体积在2年期间从5.17±5.55 cm³降至2.61±2.73 cm³(P<0.0001)。
- 痛风石尿酸体积减少70.6%,痛风石软组织体积减少37.8%(P<0.0001),尿酸体积的减少幅度大于软组织体积。
- 平均痛风石尿酸与软组织比值从基线0.15降至第2年0.05(P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The gouty tophus is an organized structure composed of monosodium urate (MSU) crystals and chronic inflammatory soft tissue. This dual-energy computed tomography (DECT) study aimed to determine whether the composition of the tophus changes during urate-lowering therapy. METHODS: Serial DECT scans from 32 people with gout were obtained over 2 years of allopurinol therapy, dose-escalated to serum urate of <0.36 mmoles/liter. Up to 5 index tophi were selected for each patient, with 103 separate tophi included in the analysis. Using manual outlining methods of conventional CT and DECT scans, the same index tophi were serially measured for total tophus volume and urate volume. For each tophus, the soft tissue volume was then calculated by subtracting the urate volume from the total tophus volume. RESULTS: The mean ± SD serum urate reduced from 0.43 ± 0.03 mmoles/liter at baseline to 0.31 ± 0.02 mmoles/liter at year 2. The mean ± SD total tophus volume reduced over the 2-year period from 5.17 ± 5.55 cm3 to 2.61 ± 2.73 cm3 (P < 0.0001). Greater reductions in tophus urate volumes than tophus soft tissue volumes were observed; the tophus urate volume decreased by 70.6%, and tophus soft tissue volume decreased by 37.8% (P < 0.0001). The mean tophus urate:soft tissue ratio reduced from 0.15 at baseline to 0.05 at year 2 (P < 0.001). CONCLUSION: The composition of the tophus is dynamic and changes during urate-lowering therapy for gout management. The soft tissue component of the tophus is slower to respond and may persist without measurable MSU crystal deposition.
引用
- Chen L, Gamble GD, Horne A, et al. Changes in Tophus Composition During Urate-Lowering Therapy: A Dual-Energy Computed Tomography Study. Arthritis Care Res (Hoboken). 2023. PMID: 36594401. doi:10.1002/acr.25084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。